Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2007
11/15/2007WO2007128782A1 Spiro- (tho) benzopyran-2, 4' -piperidine-and cyclohexane derivatives as inhibitors of specific cell cycle enzymes
11/15/2007WO2007128723A1 Ah receptor antagonists
11/15/2007WO2007128588A2 Glutadon
11/15/2007WO2007128561A1 Crystalline forms of letrozole and processes for making them
11/15/2007WO2007128557A1 Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
11/15/2007WO2007128538A1 5-urea substituted naphthalimide derivatives, methods of production and pharmaceutical compositions for treating cancer
11/15/2007WO2007128537A2 Pharmaceutical preparation based on myrtucommulone a for the selective tumour and cancer therapy
11/15/2007WO2007128344A1 Design and synthesis of biotinylated probes for n-acyl-ethanolamines
11/15/2007WO2007128231A1 Trail receptor-binding agents and uses of the same
11/15/2007WO2007128109A1 Aptamers that recognize the carbohydrate n-acetylgalactosamine (galnac)
11/15/2007WO2007112121A9 Tetracycline compounds and methods of treatment
11/15/2007WO2007106549A3 Method for treating brain cancer
11/15/2007WO2007099323A3 Quinoline derivatives
11/15/2007WO2007099171A3 Bicyclo-pyrazoles active as kinase inhibitors
11/15/2007WO2007090141A3 Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
11/15/2007WO2007084693A3 Immunoconjugates with improved efficacy for the treatment of diseases
11/15/2007WO2007076160A3 C-10 carbamates of taxanes
11/15/2007WO2007075525A3 Combination of an iap-inhibitor and a taxane7
11/15/2007WO2007058942A3 Imidazopyrazines as protein kinase inhibitors
11/15/2007WO2006135636A3 Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
11/15/2007WO2006124354A3 Tyrosine kinase inhibitors
11/15/2007WO2006122319A3 Histone deacetylase inhibitors
11/15/2007WO2006089537A8 Method for production of a preparation of a solid dmso-containing silicone oil emulsion for the binding of reactive oxygen compounds in human and animal bodies
11/15/2007US20070265449 Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
11/15/2007US20070265436 Nucleotide sequences coding tumor-associated antigenic target polypeptide specific immunoglobulins for use in detection and prevention of cell proliferative disorders
11/15/2007US20070265345 Novel Biphenyl Compounds And Their Use
11/15/2007US20070265333 For treatment of melanoma, colon cancer, and/or breast cancer
11/15/2007US20070265325 Nitro Indazole Derivatives
11/15/2007US20070265324 Such as veliparib and temozolomide; poly/adp-ribose/polymerase (PARP)
11/15/2007US20070265320 (2S,4S)-1-[[(4-carbamoylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile, for treating type II diabetes; increase glucagon-like peptide activity
11/15/2007US20070265315 An urea compounds containing a pyridine, quinoline, or isoquinoline functionality; p38 mediated diseases such as inflammation and VEGF mediated diseases such as angogenesis disorders
11/15/2007US20070265296 Nuclear receptor binding agents
11/15/2007US20070265292 N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-piperazin-1-ylmethyl-benzamide methanesulfonate; anticarcinogenic and antproliferative agent; angiogenesis inhibitor
11/15/2007US20070265289 2-Aminopyrimidine Derivative
11/15/2007US20070265288 Stable Crystal Form of Imatinib Mesylate and Process for the Preparation Thereof
11/15/2007US20070265286 Quinazoline derivatives as VEGF inhibitors
11/15/2007US20070265274 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases
11/15/2007US20070265269 Water Soluble Esters of [N-(4-Amino-2-Butynyl)] with Anticancer Activity
11/15/2007US20070265264 Thia-tetraazaacenaphthylene kinase inhibitors
11/15/2007US20070265263 Heterocyclic inhibitors of ERK2 and uses thereof
11/15/2007US20070265260 Quinazoline derivatives
11/15/2007US20070265259 Proline Derivatives
11/15/2007US20070265240 Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes
11/15/2007US20070265224 Nucleotide mimics and their prodrugs
11/15/2007US20070265213 Use of Docetaxel/Doxorubicin/Cyclophosphamide in Adjuvant Therapy
11/15/2007US20070265212 Drug Transport and Delivery System
11/15/2007US20070265208 Association of calpain inhibitors and reactive oxygen species trapping agents
11/15/2007US20070265201 Inhibitors of inflammatory cytokine transcription derived from hcmv protein ie2
11/15/2007US20070265194 Agents for the treatment of viral infections
11/15/2007US20070265188 LDL Receptor-Related Proteins 1 and 2 and Treatment of Bone or Cartilage Conditions
11/15/2007US20070264417 Procyanidins; cleaning cocoa beans, heating unroasted cocoa nibs to loosen shells, winnowing the nibs from the shells, extracting with a polar solvent, a non-polar solvent, or a supercritical fluid
11/15/2007US20070264359 administering an effective amount of an aqueous or alcohol extract of Phyllanthus to a mammal infected with the YMDD hepatitis B virus mutant strain resistant; inhibiting viral gene expression in a mammal infected with a hepatitis B virus
11/15/2007US20070264345 liquid crystal gel containing polyoxyethylene-glyceryl-trioleate, 26.7-40.0%, propylene-glycol, 13.3-20.0%, isopropyl myristate, 5.0-35.0%, ethanol, 0.01-10.0%, benzyl alcohol, 0.5-1.5%, a hyaluronic acid salt or complex 0.01-2.00%, and purified water, 12.5-26.5%; healing cosmetics
11/15/2007US20070264286 Tuberculosis Vaccines Including Recombinant BCG Strains Expressing Alanine Dehydrogenase, Serine Dehydratase and/or Glutamine Synthetase
11/15/2007US20070264283 Vaccine
11/15/2007US20070264282 Herpes virus strains for gene therapy
11/15/2007US20070264279 Compositions and methods comprising a MAGE-b antigen
11/15/2007US20070264276 Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
11/15/2007US20070264275 Peptides Derived from the Protein Mmp-2, and the Use Thereof in Antitumoral Immunotherapy
11/15/2007US20070264271 Potent Immunostimulatory from Microalgae
11/15/2007US20070264268 screening for somatomedin receptor modulators comprising contacting a mannoside polypeptide or nucleic acid bioassay with a test agent and detecting the test agents biased activity of the bioassay; drug screening; animal models
11/15/2007US20070264267 Nucleotide sequences coding zinc transport protein for use in diagnosis, prevention and treatment of cell proliferative disorders
11/15/2007US20070264266 Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents
11/15/2007US20070264260 Treatment methods using anti-CD22 antibodies
11/15/2007US20070264253 Human Anti-Epidermal Growth Factor Receptor Antibody
11/15/2007US20070264240 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation
11/15/2007US20070264232 Cell populations which co-express CD49c and CD90
11/15/2007US20070264230 Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
11/15/2007US20070264198 Tumor necrosis agent
11/15/2007US20070264195 Modulation of Activity of Neurotrophins
11/15/2007US20070264191 Materials and Methods Relating to the Treatment of Glioblastomas
11/15/2007DE102006020582A1 Verfahren zur Herstellung einer triterpensäurehaltigen wässrigen Lösung, triterpensäurehaltige wässrige Lösung und deren Verwendung A process for the preparation of a triterpenic acid aqueous solution containing triterpenic acid aqueous solution and the use thereof
11/15/2007CA2651691A1 Glutaminase and 6-diazo-5-oxo-l-norleucine (don) for cancer therapy
11/15/2007CA2651558A1 Novel compounds
11/15/2007CA2651197A1 5-urea substituted naphthalimide derivatives, methods of production and pharmaceutical compositions for treating cancer
11/15/2007CA2651152A1 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer
11/15/2007CA2650953A1 Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
11/15/2007CA2650303A1 Thienopyrimidine pharmaceutical compounds and their use
11/15/2007CA2649872A1 Trail receptor-binding agents and uses of the same
11/15/2007CA2649792A1 Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
11/15/2007CA2648947A1 Therapy targeting cathepsin s
11/15/2007CA2648831A1 Spiro- (tho) benzopyran-2, 4' -piperidine-and cyclohexane derivatives as inhibitors of specific cell cycle enzymes
11/15/2007CA2638785A1 Anti-ephb4 antibodies and methods using same
11/14/2007EP1854892A1 Modified viral surface proteins wich bind to cells of tumor vasculature
11/14/2007EP1854880A1 Methods and reagents for modulating cholesterol levels
11/14/2007EP1854808A2 Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
11/14/2007EP1854800A1 Antitumoral derivatives of Ecteinascidin ET-743
11/14/2007EP1854799A1 Process for the preparation of a taxane derivative
11/14/2007EP1854798A2 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
11/14/2007EP1854793A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY
11/14/2007EP1854787A1 Novel cyclic compound having quinolylalkylthio group
11/14/2007EP1854509A2 Methods and compositions for restoring conformational stability of a protein of the p53 family
11/14/2007EP1854487A2 Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
11/14/2007EP1854485A1 Preventives/remedies for cancer
11/14/2007EP1854474A1 Immunopotentiating agent
11/14/2007EP1854473A1 Preventive/therapeutic agent for cancer
11/14/2007EP1854469A1 Fermentation composition having immunomodulating effect
11/14/2007EP1854465A1 Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
11/14/2007EP1854464A2 Combinations comprising epothilone derivatives
11/14/2007EP1853619A1 Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
1 ... 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 ... 2211